Divestiture/carve-outOct 20, 2026Pending
🇺🇸 United States
PHPrenatal Health testing businessLLabcorp
Healthcare › Life Science Tools & Diagnostics
Enterprise value$210MEnterprise value
AnnouncedOct 20, 2026
ConsiderationCash
StructureOther
RegionNorth America
Cross-borderNo
Contingent paymentNo
Overview
Labcorp agreed to acquire Myriad Genetics' Prenatal Health testing business, which includes the Prequel, Foresight, SneakPeek, and FirstGene tests, for $210 million in cash plus the value of the business's inventory at closing.
Deal rationale
The transaction is expected to expand patient access to Labcorp's laboratory services and support Myriad's strategic priorities by sharpening its portfolio and strengthening its balance sheet.
AI-generated from the SEC filingPendingHealthcare › Life Science Tools & DiagnosticsUnited StatesNorth America
Timeline
Valuation and terms
| Equity value | Undisclosed | |
|---|---|---|
| Enterprise value | $210M | Headline figure |
| Consideration | Cash |
Advisors
Buy-side
BBarclays
Sell-side
GSGuggenheim Securities
Parties
Target
PHPrenatal Health testing business
- Headquarters
- United States
- Ticker
- —
Acquirer
LLabcorp
- Headquarters
- United States
- Ticker
- —
Seller
MGMyriad Genetics, Inc.
- Headquarters
- —
- Ticker
- —